Cargando…

Role of biologics in severe eosinophilic asthma – focus on reslizumab

Within the context of the heterogeneous phenotypic stratification of asthmatic population, many patients are characterized by moderate-to-severe eosinophilic asthma, not adequately controlled by relatively high dosages of inhaled and even oral corticosteroids. Therefore, these subjects can obtain si...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelaia, Girolamo, Vatrella, Alessandro, Busceti, Maria Teresa, Gallelli, Luca, Preianò, Mariaimmacolata, Lombardo, Nicola, Terracciano, Rosa, Maselli, Rosario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936812/
https://www.ncbi.nlm.nih.gov/pubmed/27445482
http://dx.doi.org/10.2147/TCRM.S111862
_version_ 1782441617180852224
author Pelaia, Girolamo
Vatrella, Alessandro
Busceti, Maria Teresa
Gallelli, Luca
Preianò, Mariaimmacolata
Lombardo, Nicola
Terracciano, Rosa
Maselli, Rosario
author_facet Pelaia, Girolamo
Vatrella, Alessandro
Busceti, Maria Teresa
Gallelli, Luca
Preianò, Mariaimmacolata
Lombardo, Nicola
Terracciano, Rosa
Maselli, Rosario
author_sort Pelaia, Girolamo
collection PubMed
description Within the context of the heterogeneous phenotypic stratification of asthmatic population, many patients are characterized by moderate-to-severe eosinophilic asthma, not adequately controlled by relatively high dosages of inhaled and even oral corticosteroids. Therefore, these subjects can obtain significant therapeutic benefits by additional biologic treatments targeting interleukin-5 (IL-5), given the key pathogenic role played by this cytokine in maturation, activation, proliferation, and survival of eosinophils. In particular, reslizumab is a humanized anti-IL-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids. These important therapeutic effects of reslizumab, demonstrated by several controlled clinical trials, have led to the recent approval by US Food and Drug Administration of its use, together with other antiasthma medications, for the maintenance treatment of patients suffering from severe uncontrolled asthma.
format Online
Article
Text
id pubmed-4936812
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49368122016-07-21 Role of biologics in severe eosinophilic asthma – focus on reslizumab Pelaia, Girolamo Vatrella, Alessandro Busceti, Maria Teresa Gallelli, Luca Preianò, Mariaimmacolata Lombardo, Nicola Terracciano, Rosa Maselli, Rosario Ther Clin Risk Manag Review Within the context of the heterogeneous phenotypic stratification of asthmatic population, many patients are characterized by moderate-to-severe eosinophilic asthma, not adequately controlled by relatively high dosages of inhaled and even oral corticosteroids. Therefore, these subjects can obtain significant therapeutic benefits by additional biologic treatments targeting interleukin-5 (IL-5), given the key pathogenic role played by this cytokine in maturation, activation, proliferation, and survival of eosinophils. In particular, reslizumab is a humanized anti-IL-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids. These important therapeutic effects of reslizumab, demonstrated by several controlled clinical trials, have led to the recent approval by US Food and Drug Administration of its use, together with other antiasthma medications, for the maintenance treatment of patients suffering from severe uncontrolled asthma. Dove Medical Press 2016-07-01 /pmc/articles/PMC4936812/ /pubmed/27445482 http://dx.doi.org/10.2147/TCRM.S111862 Text en © 2016 Pelaia et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Pelaia, Girolamo
Vatrella, Alessandro
Busceti, Maria Teresa
Gallelli, Luca
Preianò, Mariaimmacolata
Lombardo, Nicola
Terracciano, Rosa
Maselli, Rosario
Role of biologics in severe eosinophilic asthma – focus on reslizumab
title Role of biologics in severe eosinophilic asthma – focus on reslizumab
title_full Role of biologics in severe eosinophilic asthma – focus on reslizumab
title_fullStr Role of biologics in severe eosinophilic asthma – focus on reslizumab
title_full_unstemmed Role of biologics in severe eosinophilic asthma – focus on reslizumab
title_short Role of biologics in severe eosinophilic asthma – focus on reslizumab
title_sort role of biologics in severe eosinophilic asthma – focus on reslizumab
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936812/
https://www.ncbi.nlm.nih.gov/pubmed/27445482
http://dx.doi.org/10.2147/TCRM.S111862
work_keys_str_mv AT pelaiagirolamo roleofbiologicsinsevereeosinophilicasthmafocusonreslizumab
AT vatrellaalessandro roleofbiologicsinsevereeosinophilicasthmafocusonreslizumab
AT buscetimariateresa roleofbiologicsinsevereeosinophilicasthmafocusonreslizumab
AT gallelliluca roleofbiologicsinsevereeosinophilicasthmafocusonreslizumab
AT preianomariaimmacolata roleofbiologicsinsevereeosinophilicasthmafocusonreslizumab
AT lombardonicola roleofbiologicsinsevereeosinophilicasthmafocusonreslizumab
AT terraccianorosa roleofbiologicsinsevereeosinophilicasthmafocusonreslizumab
AT masellirosario roleofbiologicsinsevereeosinophilicasthmafocusonreslizumab